The Molecular Tumor Board Process
The molecular tumor board is often described as a meeting. In reality, it is a decision-making process, a structured way of asking whether and how genomic findings should change patient management.
The molecular tumor board is often described as a meeting. In reality, it is a decision-making process.
The goal is not only to review genomic findings but to determine whether, and how, those findings should influence patient management. Doing this well requires integrating molecular biology, pathology, clinical oncology, bioinformatics, treatment history, and the evolving scientific literature. The process is structured because genomic data alone rarely provides a complete answer.
The goal is not only to review genomic findings but to determine whether they should influence patient management, because genomic data alone rarely provides a complete answer.
The seven-step process
Every case moves through seven questions, asked in order. No step is skipped, and no conclusion is reached before the previous step is resolved.
1Technical validation
Before discussing treatment implications, the board assesses the reliability of the data:
- Sequencing quality — was it adequate?
- Tumor purity — is it sufficient?
- Are the reported alterations technically credible?
- Could any finding be an artifact?
- Is additional testing needed?
No biological interpretation should begin without confidence in the data itself.
2Biological interpretation
The next question is what is driving this tumor. Not every reported alteration is biologically significant, so the board weighs:
- Driver versus passenger alterations
- Clonal versus subclonal events
- Co-occurring alterations
- Possible resistance mechanisms
- Evidence of tumor evolution
The goal is to identify the molecular events most relevant to tumor behavior.
3Biomarker assessment
Genomic alterations are only part of the picture. Additional biomarkers can influence treatment decisions:
- MSI / dMMR
- Tumor mutational burden (TMB)
- Homologous recombination deficiency (HRD)
- Gene fusions
- Copy number alterations
- RNA expression patterns
The importance of each depends on the tumor type and clinical setting involved.
4Clinical context review
The same molecular finding can lead to different recommendations depending on the patient. The board reviews tumor type, disease stage, prior treatments, past responses, current disease burden, and performance status.
Precision oncology is not applied to a mutation; it is applied to a patient.
5Evidence review
Potential treatment options are evaluated using established evidence frameworks:
- Regulatory approvals
- Clinical practice guidelines
- Prospective trials
- Basket and umbrella trials
- Emerging evidence
- Biological rationale
Each recommendation is assigned a level of evidence, and the strength of that evidence is explicitly stated.
6Treatment prioritization
More than one option may exist at the same time; the real challenge is deciding which should come first. The board weighs expected efficacy, toxicity, accessibility, sequencing strategy, and future treatment opportunities.
The question is not whether a treatment can be given, but whether it should be given now.
7Resistance planning
Every treatment decision includes a plan for what may come next. The board evaluates known resistance pathways, possible escape mechanisms, monitoring strategies, future testing needs, and subsequent options.
Precision oncology is most effective when decisions are made one step ahead.
MTB output
The final output is not a list of mutations. It is a structured clinical interpretation. A comprehensive report answers three core questions:
1Can the data be trusted?
Technical validation.
2What is driving the tumor?
Biological interpretation.
3What should we do for this patient?
Clinical action.
These three questions form the basis of the IYGAS Three-Tier Framework.
Why molecular tumor boards matter
Modern genomic tests can generate thousands of data points. The real challenge is no longer access to information; it is determining which information matters and translating that into a clinically meaningful strategy.
A molecular tumor board exists to close exactly that gap, because the value of precision oncology is measured not by how many mutations are reported, but by the quality of the decisions that follow.
This content is for educational purposes only. It does not constitute individual medical advice and does not replace the judgment of the treating physician.
Submit a case for expert molecular review
NGS Advisory reviews your existing NGS report against current guidelines, clarifies the exact variant and its actionability for your tumor type, and delivers a structured, calibrated second opinion.